RxDoctor Payments Data

Carlos Defreitas

Optometrist · North Dartmouth, MANPI 1336136894

Payments from drug & device makers

$2,985in general payments, 2019–2025

Across 82 payments — averaging $36.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$958
  • Alcon$454
  • Bausch & Lomb Americas Inc.$441
  • AbbVie$170
  • Tarsus Pharmaceuticals, Inc.$169
  • Glaukos Corporation$146
  • plus $646 from 14 others

What the payments were for

  • Food & beverage$2,985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,985 in reported general payments places this provider in the 90th percentile of 1,084 optometrist providers in Massachusetts.

See all optometrist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$55,244
Medicare patients
343
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$9,973
VyzultaLatanoprostene Bunod15$5,999
LumiganBimatoprost13$4,728
RocklatanNetarsudil Mesylat/Latanoprost12$3,924
Latanoprost204$1,661
Prednisolone Acetate16$581
ErythromycinErythromycin Base42$476
Timolol Maleate29$412
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha29$310
Brimonidine Tartrate15$259
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$170$14,70125 claims
Bausch & Lomb Americas Inc.Vyzulta$441$5,99915 claims
Aerie Pharmaceuticals, Inc.Rocklatan$98$3,92412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,084 optometrist providers in Massachusetts.

Other optometrist in North Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →